Phase II trial of sorafenib as second line therapy in patients with advanced or metastatic gastric cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2009
At a glance
- Drugs Sorafenib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 08 Jul 2009 Actual patient number (5) added as reported by ClinicalTrials.gov.
- 22 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Feb 2008 New trial record.